MX2021006982A - Compuestos sustituidos con organofosforo como inhibidores de c met, y usos terapeuticos de los mismos. - Google Patents

Compuestos sustituidos con organofosforo como inhibidores de c met, y usos terapeuticos de los mismos.

Info

Publication number
MX2021006982A
MX2021006982A MX2021006982A MX2021006982A MX2021006982A MX 2021006982 A MX2021006982 A MX 2021006982A MX 2021006982 A MX2021006982 A MX 2021006982A MX 2021006982 A MX2021006982 A MX 2021006982A MX 2021006982 A MX2021006982 A MX 2021006982A
Authority
MX
Mexico
Prior art keywords
organophosphorus
met inhibitors
therapeutic uses
substituted compounds
triazolo
Prior art date
Application number
MX2021006982A
Other languages
English (en)
Inventor
Jirong Peng
Don Zhang
Michael Alan Green
Michael John Costanzo
Michael Nicholas Greco
Original Assignee
Beta Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beta Pharma Inc filed Critical Beta Pharma Inc
Publication of MX2021006982A publication Critical patent/MX2021006982A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/50—Organo-phosphines
    • C07F9/5004—Acyclic saturated phosphines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/30—Phosphinic acids [R2P(=O)(OH)]; Thiophosphinic acids ; [R2P(=X1)(X2H) (X1, X2 are each independently O, S or Se)]
    • C07F9/32—Esters thereof
    • C07F9/3205—Esters thereof the acid moiety containing a substituent or a structure which is considered as characteristic
    • C07F9/3211—Esters of acyclic saturated acids which can have further substituents on alkyl

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente divulgación provee derivados de [1,2,4]triazolo[4,3-b] [1,2,4]triazina, [1,2,4]triazolo[4,3-b]piridazina y [1,2,3]triazolo[4,5-b]pirazina, y sales, solvatos o profármacos farmacéuticamente aceptables de los mismos, como inhibidores de la tirosina cinasa c-MET, los cuales son útiles como agentes anticancerosos y/o antiinflamatorios novedosos.
MX2021006982A 2018-12-14 2019-12-14 Compuestos sustituidos con organofosforo como inhibidores de c met, y usos terapeuticos de los mismos. MX2021006982A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862779960P 2018-12-14 2018-12-14
PCT/US2019/066414 WO2020124060A1 (en) 2018-12-14 2019-12-14 Organophosphorus-substituted compounds as c-met inhibitors and therapeutic uses thereof

Publications (1)

Publication Number Publication Date
MX2021006982A true MX2021006982A (es) 2021-09-10

Family

ID=71077551

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021006982A MX2021006982A (es) 2018-12-14 2019-12-14 Compuestos sustituidos con organofosforo como inhibidores de c met, y usos terapeuticos de los mismos.

Country Status (15)

Country Link
US (1) US20220064194A1 (es)
EP (1) EP3893872A4 (es)
JP (1) JP2022513215A (es)
KR (1) KR20210111779A (es)
CN (1) CN113412112A (es)
AU (1) AU2019395282A1 (es)
BR (1) BR112021011547A2 (es)
CA (1) CA3122575A1 (es)
EA (1) EA202191541A1 (es)
IL (1) IL283589A (es)
MX (1) MX2021006982A (es)
SG (1) SG11202105872RA (es)
TW (1) TW202039500A (es)
WO (1) WO2020124060A1 (es)
ZA (1) ZA202104000B (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116969955B (zh) * 2023-09-25 2023-12-19 中国药科大学 一种[1,2,4]三唑[4,3-b]哒嗪类化合物及其制法与应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8030305B2 (en) 2005-12-21 2011-10-04 Janssen Pharmaceutica N.V. Triazolopyridazines as kinase modulators
NL2000613C2 (nl) * 2006-05-11 2007-11-20 Pfizer Prod Inc Triazoolpyrazinederivaten.
US20110039856A1 (en) * 2007-11-29 2011-02-17 Pfizer Inc. Polymorphs of a c-met/hgfr inhibitor
UY32049A (es) 2008-08-14 2010-03-26 Takeda Pharmaceutical Inhibidores de cmet
HUE025504T2 (en) 2009-12-31 2016-02-29 Hutchison Medipharma Ltd Triazolopyrazine derivatives, preparations and methods of application
TWI520962B (zh) * 2012-06-29 2016-02-11 As the c-Met tyrosine kinase inhibitors novel fused pyridine derivatives
CN103122000B (zh) * 2012-09-03 2013-12-25 中美冠科生物技术（太仓）有限公司 用作抗肿瘤药物的高选择性的c-Met激酶抑制剂
CN109369656B (zh) * 2015-12-31 2021-05-07 上海医药集团股份有限公司 喹啉类化合物硫酸盐的晶型、制备方法、组合物与应用

Also Published As

Publication number Publication date
TW202039500A (zh) 2020-11-01
KR20210111779A (ko) 2021-09-13
JP2022513215A (ja) 2022-02-07
SG11202105872RA (en) 2021-07-29
AU2019395282A1 (en) 2021-07-08
BR112021011547A2 (pt) 2021-08-31
WO2020124060A1 (en) 2020-06-18
IL283589A (en) 2021-07-29
US20220064194A1 (en) 2022-03-03
ZA202104000B (en) 2022-08-31
CN113412112A (zh) 2021-09-17
EP3893872A4 (en) 2022-08-10
EP3893872A1 (en) 2021-10-20
CA3122575A1 (en) 2020-06-18
EA202191541A1 (ru) 2022-01-21

Similar Documents

Publication Publication Date Title
PH12019500775A1 (en) Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors
NZ744349A (en) Pyrazolo[1,5-a]pyrazin-4-yl derivatives as jak-inhibitors
PH12019500776A1 (en) Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors
PH12018500121A1 (en) Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors
PH12019501670A1 (en) Kras g12c inhibitors and methods of using the same
WO2016142855A3 (en) Pyrazolo[1,5-a][1,3,5]triazine and pyrazolo[1,5-a]pyrimidine derivatives as cdk inhibitors
NZ736055A (en) Imidazopyrazines and pyrazolopyrimidines and their use as ampa receptor modulators
MX2020009586A (es) Compuestos de (2-azabiciclo[3.1.0]hexan-2-il)pirazolo[1,5-a]pirimi dina e imidazo[1,2-b]piridazina sustituidos como inhibidores de cinasas trk.
MX2018013133A (es) Compuesto de pirazolo[1,5-a]pirimidina.
MX2021009439A (es) Derivados de imidazo [2,1-f] [1,2,4] triazin-4-amina como agonista de tlr7.
EP4249071A3 (en) Benzoazepine analogs as inhibiting agents for bruton's tyrosine kinase
MX2015012896A (es) Inhibidores de pirrolo [2,3-b] piridina cdk9 cinasa.
MX2019006612A (es) Derivados de imidazo[1,5-a]pirazina como inhibidores de fosfatidilinositol-4,5-bisfosfato 3-quinasadelta (pi3kdelta).
PH12020551343A1 (en) 7-substituted sulfonimidoylpurinone compounds and derivatives for the treatment and prophylaxis of liver cancer
MX2021006982A (es) Compuestos sustituidos con organofosforo como inhibidores de c met, y usos terapeuticos de los mismos.
IL280122A (en) Imidazo[2,1-B]pyridazine derivatives as TRK inhibitors
PH12020551583A1 (en) Anticancer pharmaceutical compositions for combined therapy
PH12019500478A1 (en) 8-(azetidin-1-yl)-[1,2,4]triazolo[1,5-a]pyridinyl compounds, compositions and methods of use thereof
EA201990940A1 (ru) ЗАМЕЩЕННЫЕ ПИРАЗОЛО[1,5-a]ПИРИДИНОВЫЕ СОЕДИНЕНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ RET КИНАЗЫ
EA201990939A1 (ru) ЗАМЕЩЕННЫЕ ПИРАЗОЛО[1,5-a]ПИРИДИНОВЫЕ СОЕДИНЕНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ RET КИНАЗЫ
MX2017002749A (es) Metodo para la preparacion de imidazopiridazinas sustituidas.